Cellular senescence: a key therapeutic target in aging and diseases.
Zhang L, Pitcher LE, Yousefzadeh MJ, Niedernhofer LJ, Robbins PD, Zhu Y. · 2022
Read Cellular senescence: a key therapeutic target in aging and diseases. by Zhang L, Pitcher LE, Yousefzadeh MJ, Niedernhofer LJ, Robbins PD, Zhu Y. (2022) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc9337830.txt.
Introduction
Zhang and co-authors review cellular senescence as a treatment target in aging and disease. Senescent cells have left the cell cycle for good after damage or stress. They release a harmful mix of signals that spreads senescence and breaks tissue balance. Mouse models where these cells can be deleted show they drive much age-related decline.
Two drug families aim at these cells. Senolytics kill them; senomorphics mute their harmful signals. Early trials in people suggest real benefit, and more trials are under way. The review covers how the cells form and mark themselves. It also tracks how candidate drugs are found and tested. The authors see senescence control as a core strategy against aging diseases.
Catalog record
| CREATOR | Zhang L, Pitcher LE, Yousefzadeh MJ, Niedernhofer LJ, Robbins PD, Zhu Y. |
|---|---|
| YEAR | 2022 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 73 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Cellular senescence: a key therapeutic target in aging and diseases By Lei Zhang, Louise E Pitcher, Matthew J Yousefzadeh, Laura J Niedernhofer, Paul D Robbins, Yi Zhu Published in: The Journal of Clinical Investigation DOI: 10.1172/JCI158450 ABSTRACT Abstract Cellular senescence is a hallmark of aging defined by stable exit from the cell cycle in response to cellular damage and stress. Senescent cells (SnCs) can develop a characteristic pathogenic senescence-associated secretory phenotype (SASP) that drives secondary senescence and disrupts tissue homeostasis, resulting in loss of tissue repair and regeneration. The use of transgenic mouse models in which SnCs can be genetically ablated has established a key role for SnCs in driving aging and age-related disease. Importantly, senotherapeutics have been developed to pharmacologically eliminate SnCs, termed senolytics, or suppress the SASP and other markers of senescence, termed senomorphics. Based on extensive preclinical studies as well as small clinical trials demonstrating the benefits of senotherapeutics, multiple clinical trials are under way. This Review discusses the role of SnCs in aging and age-related diseases, strategies to target SnCs, approaches to discover and develop senotherapeutics, and preclinical and clinical advances of senolytics. INTRODUCTION Aging is a complex process driven, at least in part, by hallmarks of aging, including cellular senescence, genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient sensing, mitochondrial dysfunction, stem cell exhaustion, and altered intercellular communication (1, 2). Of these hallmarks, cellular senescence has been directly implicated as a key driver of aging and age-related diseases. Senescent cells (SnCs) are characterized by stable exit from the cell cycle and loss of proliferative capacity, even in the presence of mitogenic stimuli (3). The phenomenon of cellular senescence was first described by Leonard Hayflick and Paul Moorhead in 1961 using diploid fibroblast cell lines, which failed to further divide after 40–60 population doublings (4). In addition to replicative senescence caused by telomeric erosion and induction of a DNA damage response, cellular senescence can be induced by other stressors, including but not limited to epigenetic changes, genomic instability, mitochondrial dysfunction, reactive metabolites, oxidative stress, inactivation of certain tumor suppressor genes, oncogenic- and therapy-induced stress, and viral infections (Figure 1) (3, 5–12). [Figure: Diverse stress stimuli can induce cellular senescence and lead to generation of senescent cells, which play pleiotropic roles in both physiology and pathology.CCF, cytoplasmic chromatin fragment; DNA-SCARS, DNA segments with chromatin alterations reinforcing senescence; mtDNA, mitochondrial DNA; SADF, senescence-associated DNA damage foci; SAHF, senescence-associated heterochromatin foci; SAMD, senescence-associated mitochondrial dysfunction; SASP, senescence-associated secretory phenotype; TAF, telomere-associated foci.] SnCs exhibit molecular features (e.g., expression of senescence markers) and morphological features (e.g., enlarged, flattened appearance) that make them distinguishable from normal cells (Figure 1) (13). Lysosomal hydrolase activity at pH 6.0 resulting from enhanced lysosomal biogenesis, termed senescence-associated β-galactosidase (SA-β-gal), and accumulation of cytoplasmic granules in the lysosomes leading to an enlarged hypertrophic morphology are prominent phenotypes of SnCs (3, 14). The cellular senescence program is initiated by the p16INK4a/Rb and/or p53/p21CIP1 tumor suppressor pathways. p16INK4a, p21CIP1, and p53 are cyclin-dependent kinase inhibitors and a tumor suppressor that act in a coordinated manner and/or independently to arrest cell cycles in G1 (15–17). Expression of p16INK4a, known to increase in mammalian tissue with age, is a prominent marker of cellular senescence (18–20). For example, p16INK4a expression in CD3+ human peripheral blood T lymphocytes is a robust marker of chronological and biological age (21). In addition to increased p16INK4a and p21CIP1 expression, SnCs have reduced lamin B1, reflecting disruption of the nuclear lamina observed during senescence (22), which is emerging as another hallmark of SnCs (23). Epigenetic changes in SnCs create an environment that is permissive to the deregulation of transposable elements like LINE-1, whose increased expression is observed in late senescence (24, 25). Furthermore, SnCs are characterized by the presence of DNA damage–associated features such as DNA segments with chromatin alterations reinforcing senescence (DNA-SCARS) and senescence-associated heterochromatin foci (26, 27). These alterations in the nuclear architecture of the genome are potentially involved in determining the cell fate decision for cellular senescence (28). Although SnCs are growth arrested in the cell cycle, they are still metabolically active (8). Many SnCs secrete a wide spectrum of bioactive factors, including inflammatory cytokines, chemokines, growth factors, matrix metalloproteinases, lipids, nucleotides, extracellular vesicles, and soluble factors, termed the senescence-associated secretory phenotype (SASP) (29). In addition, the release of DNA from the nucleus, termed cytoplasmic chromatin fragments, resulting from nuclear-cytoplasmic blebbing, mitochondrial DNA, NF-κB signaling, and the C/EBPβ transcription cofactor is an important factor in priming the SASP (30–32). SENESCENT CELLS IN AGING AND AGE-RELATED DISEASES Cellular senescence is thought to have evolved as an antitumor mechanism where the SASP induced by oncogene-induced senescence recruits immune cells to facilitate SnC removal (33, 34). SnCs are heterogeneous in nature and emerge throughout life due to various stimuli. In addition to heterogeneity, SnCs are also pleiotropic in function. SnCs play an essential role in multiple physiological processes, including embryogenesis, cellular reprogramming, tissue regeneration, wound healing, immunosurveillance, and tumor suppression (35–41). However, SnCs can also contribute to the pathology of many chronic diseases, including diabetes, cancer, osteoarthritis, and Alzheimer’s disease (Figure 1) (42, 43). SnCs accumulate with age in most tissues, and SASP factors can act in both proximal and distal fashions to induce secondary senescence, thus propagating and enhancing the SnC burden (3, 29). The SASP also serves to sustain and enhance inflammaging, whereby enhanced chronic, low-grade systemic inflammation occurs in the absence of pathogenic processes (44, 45). The use of p16Ink4a-high senescent cell reporter mice (p16LUC and p16-CreERT2-tdTomato mice) revealed that p16Ink4a-expressing SnCs progressively increased with age and drove aging and cancer processes in mice (18, 46, 47). In several mouse models of accelerated aging, Ercc1–/Δ and Bub1bH/H hypomorphic mice develop genomic instability with accelerated accumulation of SnCs, resulting in premature aging symptoms including shortened lifespan and increased histopathological lesions in various organs (48–50). Use of a transgenic p16Ink4a-expressing SnC removal system in mice, termed INK-ATTAC, provided further evidence of a key role for SnCs in aging and disease. This model enables selective clearance of SnCs using the promoter of p16Ink4a combined with an FKBP–caspase-8 suicide transgene that induces apoptosis of p16Ink4a-high SnCs through targeted activation of caspase-8 (51) with an FKBP dimerizer. This genetic clearance strategy was first applied in Bub1bH/H-progeroid mice, in which it blunted age-related pathologies including sarcopenia, cataracts, and lipodystrophy (51). The INK-ATTAC model also was used to demonstrate the beneficial consequences of SnC clearance in naturally aged mice, where it improved healthspan, extended median lifespan, and delayed tumorigenesis. Cellular senescence not only contributes to aging but also plays a causal role in numerous age-related diseases. SnC accumulation frequently occurs at pathogenic sites in many major age-related chronic diseases, including Alzheimer’s and cardiovascular diseases, osteoporosis, diabetes, renal disease, and liver cirrhosis (52–56). Notably, transplanting a small number of SnCs into young healthy animals recapitulates age-related impaired physical functions (57, 58). This supports the threshold hypothesis, which proposes that once the SnC burden increases beyond sustainability in a tissue, it activates age-related pathological changes and eventually results in disease. Genetic clearance of p16Ink4a-high SnCs in the INK-ATTAC mouse models has demonstrated the benefit of SnC clearance in the prevention or alleviation of diseases including osteoporosis, frailty, atherosclerosis, hepatic